Advertisement

Topics

Omeros Responds to Statnews.com Story

11:00 EDT 23 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Omeros Corporation (NASDAQ:OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” a...

Other Sources for this Article

Cook Williams Communications, Inc.
Jennifer Cook Williams, 360-668-3701
Investor and Media Relations
jennifer@cwcomm.org

NEXT ARTICLE

More From BioPortfolio on "Omeros Responds to Statnews.com Story"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...